Ayisha joined Scrip in 2021 after working as an investigative reporter at GlobalData's pharmaceutical news platform, BioPharm Insight, where she covered the beats of hematology, oncology and rare diseases. She holds an MA in Philosophy from University College London and an NCTJ diploma in multimedia journalism. Ayisha is interested in psychiatric disorders and drug development focused on the microbiome.
Latest From Ayisha Sharma
Part One Disappointment For BioXcel’s Igalmi In Pivotal Agitation Trial
The US firm’s drug for schizophrenia- and bipolar-related agitation Igalmi has failed part one of a pivotal trial in at-home patients, but the option for higher dosing in part two combined with placebo-like safety could offer hope.
Mirati’s Pivotal NSCLC Disappointment For Sitravatinib Combo ‘Unsurprising’
The US firm’s kinase inhibitor fell short of overall survival expectations in combination with a PD-1 inhibitor in an advanced lung cancer trial, but upcoming milestones for Krazati may be more of a concern.
Oculis Eyes Double DIAMOND After Initial Phase III Success In DME
The Swiss firm’s lead candidate has hit the mark in the first stage of a pivotal diabetic macular edema program, edging closer to becoming the first eye drop treatment for a condition where unmet need remains despite the advent of anti-VEGFs.
Sanofi’s Dupixent Has Greater Benefit In COPD Patients With Higher Type II Inflammation
The IL-4/IL-3 inhibitor attained a greater reduction in exacerbations in patients with a higher level of a biomarker for type 2 inflammation according to complete pivotal data, but questions remain on the timing of regulatory filings.
Poxel Looks To More Twymeeg Partnerships In Asia To Pay Off Debt
The French firm’s antidiabetic drug has enjoyed some traction in the Japanese market following the end of launch year restrictions, raising hopes that other Asian partnerships could help improve its financial position.
Swiss Talent And Innovation ‘Needs More Financing To Flourish’
With excellent academic centers and a thriving start-up scene, Switzerland’s biotech scene has garnered significant interest in recent years. However, without being a priority for EU funds, the sector remains reliant on foreign cash and needs a funding push from within to boost success.